Kenneth A Lichtenstein

Summary

Country: USA

Publications

  1. ncbi Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients
    Kenneth A Lichtenstein
    Rose Medical Center, Unviersity of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    J Acquir Immune Defic Syndr 32:48-56. 2003
  2. ncbi Redefining lipodystrophy syndrome: risks and impact on clinical decision making
    Kenneth A Lichtenstein
    University of Colorado Infectious Disease Group Practice, Denver, 80262, USA
    J Acquir Immune Defic Syndr 39:395-400. 2005
  3. ncbi Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort
    Kenneth A Lichtenstein
    Rose Medical Center, Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 40:148-57. 2005
  4. pmc Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients
    Kenneth A Lichtenstein
    National Jewish Health, Denver, CO, USA
    Prev Chronic Dis 10:E10. 2013
  5. doi Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study
    Kenneth A Lichtenstein
    National Jewish Medical and Research Center, Denver, Colorado 80206, USA
    Clin Infect Dis 51:435-47. 2010
  6. ncbi Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency
    Kenneth A Lichtenstein
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:27-35. 2008
  7. ncbi The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study
    Frank J Palella
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Ann Intern Med 151:73-84. 2009
  8. doi Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006
    Benjamin Young
    Rocky Mountain CARES DIDC, Denver, Colorado 80220, USA
    Clin Infect Dis 52:1061-8. 2011
  9. ncbi Antiretroviral treatment interruptions and risk of non-opportunistic diseases
    Kenneth A Lichtenstein
    National Jewish Health, 1400 Jackson Street, G 316, Denver, CO 80206, USA
    Curr HIV/AIDS Rep 6:77-82. 2009
  10. ncbi Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection
    Jennifer J Kiser
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Pharmacotherapy 26:511-4. 2006

Collaborators

Detail Information

Publications19

  1. ncbi Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients
    Kenneth A Lichtenstein
    Rose Medical Center, Unviersity of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    J Acquir Immune Defic Syndr 32:48-56. 2003
    ..Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy...
  2. ncbi Redefining lipodystrophy syndrome: risks and impact on clinical decision making
    Kenneth A Lichtenstein
    University of Colorado Infectious Disease Group Practice, Denver, 80262, USA
    J Acquir Immune Defic Syndr 39:395-400. 2005
    ....
  3. ncbi Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort
    Kenneth A Lichtenstein
    Rose Medical Center, Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 40:148-57. 2005
    ..We sought to identify factors associated with the clinical diagnosis of symmetrical peripheral neuropathy (SPN) during the era of highly active antiretroviral therapy (HAART) in a retrospective, longitudinal cohort analysis...
  4. pmc Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients
    Kenneth A Lichtenstein
    National Jewish Health, Denver, CO, USA
    Prev Chronic Dis 10:E10. 2013
    ..We investigated physicians' compliance with NCEP guidelines to reduce cardiovascular disease (CVD) risk in a population infected with HIV...
  5. doi Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study
    Kenneth A Lichtenstein
    National Jewish Medical and Research Center, Denver, Colorado 80206, USA
    Clin Infect Dis 51:435-47. 2010
    ..We investigated the association of low CD4(+) T lymphocyte cell count with incident CVD in a cohort of outpatients treated in 10 HIV specialty clinics in the United States...
  6. ncbi Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency
    Kenneth A Lichtenstein
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:27-35. 2008
    ..US guidelines recommend deferring initiation of highly active antiretroviral therapy (HAART) for most patients with CD4 counts >350 cells/mm in part because of concerns about antiretroviral toxicity...
  7. ncbi The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study
    Frank J Palella
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Ann Intern Med 151:73-84. 2009
    ..HIV-1 genotypic and phenotypic susceptibility testing (GPT) optimizes antiretroviral selection, but its effect on survival is unknown...
  8. doi Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006
    Benjamin Young
    Rocky Mountain CARES DIDC, Denver, Colorado 80220, USA
    Clin Infect Dis 52:1061-8. 2011
    ..Among persons with HIV infection, low bone mineral density is common and has raised concerns about increased risk of fracture...
  9. ncbi Antiretroviral treatment interruptions and risk of non-opportunistic diseases
    Kenneth A Lichtenstein
    National Jewish Health, 1400 Jackson Street, G 316, Denver, CO 80206, USA
    Curr HIV/AIDS Rep 6:77-82. 2009
    ..Structured treatment interruptions should be avoided in the management of HIV-infected individuals...
  10. ncbi Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection
    Jennifer J Kiser
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Pharmacotherapy 26:511-4. 2006
    ....
  11. doi A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses
    Kenneth A Lichtenstein
    Division of Infectious Diseases, Department of Medicine, National Jewish Health, Denver, CO, USA
    Antivir Ther 17:1301-9. 2012
    ..Chronic inflammation from persistent immune activation could contribute to this poor response, resulting in HIV-1 disease progression and the development of some non-HIV-1 comorbidities...
  12. ncbi Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome
    Lisa A Kosmiski
    Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Metabolism 52:620-5. 2003
    ..The increase in TEE appears to be due to increases in REE. The pathogenesis of elevated EE in HIV lipodystrophy and other forms of lipodystrophy remains to be determined...
  13. ncbi The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities
    Peter L Anderson
    University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Clin Infect Dis 38:743-53. 2004
    ..Such research should include comparisons of NRTI phosphorylation according to sex and cellular activation state (i.e., elevated vs. low)...
  14. ncbi A 7-year longitudinal analysis of IL-2 in patients treated with highly active antiretroviral therapy
    Kenneth A Lichtenstein
    AIDS 18:2346-8. 2004
  15. doi Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005
    Kate Buchacz
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS 22:1345-54. 2008
    ..To assess temporal trends in the rates of hospitalizations and associated diagnoses among HIV-infected patients before and during the era of highly active antiretroviral therapy...
  16. ncbi Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003
    Pragna Patel
    Centers for Disease Control and Prevention, Emory University, and Northrop Grumman Information Technology, Atlanta, Georgia 30333, USA
    Ann Intern Med 148:728-36. 2008
    ..Persons who are HIV-infected may be at higher risk for certain types of cancer than the general population...
  17. doi Human immunodeficiency virus-associated lipoatrophy: letting the genome out of the bottle
    Kenneth A Lichtenstein
    J Infect Dis 197:784-6. 2008
  18. ncbi Atazanavir-containing renal calculi in an HIV-infected patient
    Peter L Anderson
    AIDS 21:1060-2. 2007
  19. ncbi The case for earlier treatment of HIV infection
    Scott D Holmberg
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Clin Infect Dis 39:1699-704. 2004
    ..Given these accumulating data, we believe reconsideration of the "when-to-start" question is timely and justified...